Beyond genomics

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 4, 2007, Pages 366-370

  Dollery, C T ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II ANTAGONIST; BCR ABL PROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CODEINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG METABOLIZING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; IMATINIB; METOPROLOL; PAROXETINE; SORIVUDINE; TRASTUZUMAB; WARFARIN;

BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL PHARMACOLOGY; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG INDUSTRY; DRUG METABOLISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC PROCEDURES; GENOME ANALYSIS; GENOMICS; HEALTH CARE COST; HUMAN; HUMAN GENOME; HYPERTENSION; PHYSIOLOGY; PRIORITY JOURNAL; PURCHASING; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS; DRUG DESIGN; DRUG INDUSTRY; GENOME, HUMAN; GENOMICS; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; PHYSIOLOGICAL PROCESSES; PHYSIOLOGY; RESEARCH DESIGN; SYSTEMS BIOLOGY;

EID: 34548681425     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100363     Document Type: Review

References (12)

1. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
2. Hopkins, A.L. & Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 1, 727-730 (2002).
3. Frayling, T.M. et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316, 889-894 (2007).
4. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
5. Academy of Medical Sciences and The Royal Academy of Engineering. Systems Biology: A Vision for Engineering and Medicine 〈http://www.raeng.org.uk/ policy/engagement/pdf/Systems_Biology_Report.pdf〉 (February 2007).
6. Wei, X., McLeod, H.L., McMurrough, J., Gonzalez, F.J. & Fernandez-Salguero, P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98, 610-615 (1996).
7. Okuda, H. et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs [corrected and republished from Drug Metab. Dispos. 25, 270-273 1997, PMID: 9029059]. Drug Metab. Dispos. 25, 270-273 (1997).
8. Jain, K.K. Applications of AmpliChip CYP450. Mol. Diagn. 9, 119-127 (2005).
9. Wald, N.J. & Law, M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419 (2003).
10. National Institute for Health and Clinical Excellence 〈http://www.nice.org.uk〉.
11. Krueger, K.P., Felkey, B.G. & Berger, B.A. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J. Am. Pharm. Assoc. 43, 668-679 (2003).
12. Orser, B.A. Lifting the fog around anesthesia. Sci. Am. 296, 54-61 (2007).